

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2906683

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DAVID A JOHNSON	04/10/2014
DAVID BURKHART	04/10/2014
NUPUR DUTTA	04/15/2014
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE BIOLOGICALS S.A.
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	B-1330
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	IB1459731
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	919 483 2370
Email:	usciprtp@gsk.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	FIVE MOORE DRIVE
Address Line 2:	PO BOX 13398
Address Line 4:	RESEARCH TRIANGLE PA, NORTH CAROLINA 27709
ATTORNEY DOCKET NUMBER:	VR65346WO
NAME OF SUBMITTER:	MARILYN SALEEBY
SIGNATURE:	/Marilyn Saleeby/
DATE SIGNED:	06/20/2014
Total Attachments: 6	
source=VR65346 WO Assignment#page1.tif	
source=VR65346 WO Assignment#page2.tif	
source=VR65346 WO Assignment#page3.tif	
source=VR65346 WO Assignment#page4.tif	

PATENT

source=VR65346 WO Assignment#page5.tif

source=VR65346 WO Assignment#page6.tif

Assignment

WHEREAS I/WE, David A. JOHNSON and David BURKHART, both citizens the United States of Hamilton, Mt, and Nupur DUTTA a citizen of India of Vernon Hills, IL, (hereinafter called "the inventor(s)") have invented or discovered certain improvements in "Composition for Buffered Aminoalkyl Glucosaminide Phosphate Compounds and Its Use" (hereinafter referred to as "the invention and improvements") for which priority application 61/791165 was filed on 15 Mar 2013 in the United States, and for which a PCT international application PCT/IB2014/059731 was filed on 13 Mar 2014, designating the United States of America.

WHEREAS GLAXOSMITHKLINE BIOLOGICALS S.A., a company incorporated in Belgium, whose registered office is at Rue de L'Institut 89, B-1330 Rixensart, Belgium, is desirous of acquiring the whole right, title and interest in and to the invention, and in and to any applications for the invention and any Letters Patent to be obtained therefor, in all countries, including the United States of America, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, the inventors, hereby confirm the ownership by GLAXOSMITHKLINE BIOLOGICALS S.A. of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in and to the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in and to the invention and to the application based on the law of Belgium), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and to the application, including the right to claim priority from the application in respect of any subsequent applications, to GLAXOSMITHKLINE BIOLOGICALS S.A. in all countries, including the United States of America, its territories and possessions;

AND I/we, the inventors, hereby assign and transfer to GLAXOSMITHKLINE BIOLOGICALS S.A., my/our whole right title and interest in and to the invention and the application, and in and to any divisional application, continuation or continuation-in-part

application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof, and I/we the inventor(s) hereby authorise and request any patent arising therefrom, in all countries, including the United States, its territories and possessions, be issued to GLAXOSMITHKLINE BIOLOGICALS S.A..

AND, I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree at the request and cost of GLAXOSMITHKLINE BIOLOGICALS S.A., to provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in said GLAXOSMITHKLINE BIOLOGICALS S.A., its successors and assigns, the whole right, title and interest in and to the invention hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.


IN WITNESS WHEREOF, and with effect from 15 Mar 2013, I/we the inventors and the Attorney & Authorised Official of GLAXOSMITHKLINE BIOLOGICALS S.A. have hereunto set my/our respective hand(s).

Inventor Name

Signature


Date

David A. JOHNSON:



10 APR 2014

David BURKHART:




10 April 2014

Nupur DUTTA: _____

SIGNED by John L. Lewandowski

As the Attorney & Authorised Official of GLAXOSMITHKLINE BIOLOGICALS S.A.:


Signature

Date: 12 May 2014

Assignment

WHEREAS I/WE, David A. JOHNSON and David BURKHART, both citizens the United States of Hamilton, Mt, and Nupur DUTTA a citizen of India of Vernon Hills, IL, (hereinafter called "the inventor(s)") have invented or discovered certain improvements in "Composition for Buffered Aminoalkyl Glucosaminide Phosphate Compounds and Its Use" (hereinafter referred to as "the invention and improvements") for which priority application 61/791165 was filed on 15 Mar 2013 in the United States, and for which a PCT international application PCT/IB2014/059731 was filed on 13 Mar 2014, designating the United States of America.

WHEREAS GLAXOSMITHKLINE BIOLOGICALS S.A., a company incorporated in Belgium, whose registered office is at Rue de L'Institut 89, B-1330 Rixensart, Belgium, is desirous of acquiring the whole right, title and interest in and to the invention, and in and to any applications for the invention and any Letters Patent to be obtained therefor, in all countries, including the United States of America, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, the inventors, hereby confirm the ownership by GLAXOSMITHKLINE BIOLOGICALS S.A. of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in and to the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in and to the invention and to the application based on the law of Belgium), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and to the application, including the right to claim priority from the application in respect of any subsequent applications, to GLAXOSMITHKLINE BIOLOGICALS S.A. in all countries, including the United States of America, its territories and possessions;

AND I/we, the inventors, hereby assign and transfer to GLAXOSMITHKLINE BIOLOGICALS S.A., my/our whole right title and interest in and to the invention and the application, and in and to any divisional application, continuation or continuation-in-part

SIGNED by John L. Lemonowicz

As the Attorney & Authorised Official of GLAXOSMITHKLINE BIOLOGICALS S.A.:

John L. Lemonowicz Date: 12 May 2014
Signature